U.Approved for use through 07/31/2006. OMB 0651-0031

S Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a callection of information united is condains a said OMB control number.

Substitute for for	m 1449A/PTO		Complete if Known			
			Application Number	10/560,650		
INFORM	ATION DIS	CLOSURE	Filing Date	05-09-2006		
STATEMENT BY APPLICANT		First Named Inventor	David B. Weiner			
			Art Unit	To be determined 1632		
(Use as many sheets as necessary)			Examiner Name	To be deferring Heng Winston Sh		
Sheet 1	of	24	Attorney Docket Number	133171.02001		

			U.S. PATE	NT D	OCUME	NTS			
Examiner Initials	Cite No.1	Document Number  Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY  Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Rele Passages or Relevant Figures Appear				
	AA	US-5,593,972	01-14-199	7	Davi	d B. Wei	ner et al.		
	AB	US-5,739,118	04-14-199	18	Richar	d A. Car	rano et al.		
	AC	US-5,817,637	10-06-1998			d B. Wen			
	AD	US-5,830,876	11-03-199				neret al.		
	AE	US-5,962,428	10-05-1999		Richar	d A. Car	rano et al.		
	AF	US-5,981,505	11-09-199	19			neret al.		
	AG	US-5,580,859	12-03-199	6	Phili	p L. Felg	ner et al.		
	AH	US-5,703,055	12-30-1997 Philip L. Felgner et al.		ner et al.				
	Al	US-5,676,594	10-14-199	10-14-1997 Egbertus M. Joosten et al.					
	AJ	US-4,945,050	07-31-1990 John C. Sanford et al.		ord et al.				
	AK	US-5,036,006	07-30-199	7	John	John C. Sanford et al.			
	AL	US-5,593,972	01-14-199	7	Davi	d B. Wei	ner et al.		
	AM	US-5,840,530	11-24-299	18	Ulrich A. Gubler et al.		oler et al.		
	AN	US-4,722,848	02-02-199	8		zo Paolet			
	AO	US-5,017,487	05-21-199	1	Hendrik G. Stunnenberg et				
	AP	US-5,077,044	12-31-199	1	Bruce /	Amold D	. Stocker et		
	AQ	US-5,110,587	05-05-199	2	En	zo Paolet	ti et al.		
	AR	US-5,112,749	05-12-199	2	Rob	ert N. Br	ey et al.		
	AS	US-5,174,993	12-29-199	12	En	zo Paolet	ti et al.		
	AT	US-5,223,424	06-29-199	13	Mark	D. Coch	ran et al.		
			FOREIG	N PA	TENT D	OCUME	NTS		
Examiner	Cite	Foreign Patent Document			blication	Name	of Patentee or	Pages, Columns, Lines, Where Relevant	
Initials*	No.1			٠.	Date Applicant of Cited Document			Passages or Relevant Figures Appear	T <sup>6</sup>
	AU	PCT/US94/0089	19	08-	04-1994	David	Weiner et al.		
-	-					l		- Contraction of the Contraction	-
								and the same of th	
			-				and the same of th		
				-					
						-	-		
				_		_		The state of the s	_
	<del></del>			<u> </u>		<u> </u>			-
Examiner Signature		/Wu-Cheng Winsto	n Shen/		Date Conside	ered		07/05/2008	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Indiade convertible converti

and not considered. Include copy of this form with next communication to applicant
Applicant's unique citation designation number (optonia). 2-Applicant is unjue citation designation in stratched.
This collection of information is required by 3T CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFT to process) an application Conditionalisty as governed by 38 U Set. 2.22 and 3T CFR 1.14. This collection is estimated to base 2-bruss to complete, including gashering, preparing, and submitting the completed application form to the USFT. There will vary depending upon the individual information Officer. U.S. Patent and Trademark Officer, U.S. Department of Commercion, 2.D. Rev. 450, Alexandria, VA, 2213-14(b) DNT SEMD.
FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 2231-31-01.

PTO/SB/08A (07-05)

Approved for use through 07/31/2006 OMB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERC
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERC
Under the Papework Reduction Act of 1995, no persons are required to respond to a collection of information unless

133171.02001

Substitute for form 1449A/PTO		Complete if Known
	Application Number	10/560,650
INFORMATION DISCLOSURE	Filing Date	05-09-2006
STATEMENT BY APPLICANT	First Named Inventor	David B. Weiner
	Art Unit	To be determined 1632
(Use as many sheets as necessary)	Examiner Name	Fretzerstatement WII-C

of 24

Sheet 2

be determined 1632
be determined /Wu-Cheng Winston Shen/

Examiner	Cite	Document Number	Publication D	hato		Patentee or Applicant	of	Pages, Columns, Lines, Where	Deference
Initials *	No.1	Number - Kind Code <sup>2</sup> (if known)			offe Cited Document		- 1	Passages or Relevant Figures Appear	
	AV	US-5,225,336	07-06-199	13	En	zo Paoletti et al.	$\neg$		
	AW	US-5,240,703	08-31-199	13	Mark	D. Cochran et al.	$\neg$		
	AX	US-5,242,829	09-07-199	13	Denn	is L. Panicali et al.			
	AY	US-5,294,441	03-15-199	4		y Curtiss et al.			
	AZ	US-5,294,548	03-15-199	4	James	H. Mclinden et al			
	BA	US-5,310,668	05-10-199	4	Ron	ald W. Ellis et al.			
	BB	US-5,387,744	02-07-199	95	Re	y Curtiss et al.	$\neg$		
	BC	US-5,389,368	02-14-199	95	Ro	y Curtiss et al.			
	BD	US-5,424,065	06-13-199	5	Re	y Curtiss et al.	丁		
	BE	US-5,451,499	09-19-199	95	Mark	D. Cochran et al.	$\neg$		
	BF	US-5,453,364	09-26-199	95	En	zo Paoletti et al.	_		
	BG	US-5,462,734	10-31-199	95	Geoffrey J. Letchworth et		t t		
	BH	US-5,470,734	11-28-199	95	Paulus Sondermeijer et al.		ıl.		
	BI	US-5,482,713	01-09-199	6	Enzo Paoletti et al.		_		
	BJ	US-2002/0123099	09-05-200	12		Weiner et al.			
	ВК	US-5,840,530	11-24-299	18	Ulric	Ulrich A. Gubler et al.			
**********	****************	-							Henry
			-	************		-			
			-			-			
-	***************								Merculation
			OREIGN PA	TEN	DOCU	MENTS			
Examiner	Cite	Foreign Patent Document				Name of Patentee	2	Pages, Columns, Lines,	
Initials*	No.1	Country Code <sup>3</sup> – Number <sup>4</sup> - Kind	Code <sup>5</sup> (if known)		blication Date Applicant of Cited Document		ď	Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	KO	WO 02/29088 A	12	04-1	11-2002	David Weiner e	t al.		_
KP KQ		WO 01/24818	4	04-1	2-2001	D.G.J. Rea			
		WO 01/85920	4	11-1	5-2001	Jacques F. Banchereau et	al.		
-	-								***********
			-				******		
					-		-		
	Acres and the latest designation of the late							The state of the s	

Attorney Docket Number

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached This collection of information is required by 37 CFR 184 b. The information is required to obtain or retinal a herefit by the public which is to be fear of by the USPTO to process) an application. Confidentiality is governed by 35 U.S. C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preprint, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burder, showlide be sent to the Chile information Office. U.S. Patent and Trademark Office. U.S. Department of Commerce, P.O. Box 4450, Alexandria, VA. 2231-450, DOTS CSMD. FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA. 2231-31-310.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

1	Substitute for form 1449BiPTO			Complete if Known		
ı	INFO	MATION	DIS	CLOSUBE	Application Number	10/560,650
l	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	05-09-2006		
l	SIAI	EMENIB	ťΑ	PPLICANT	First Named Inventor	David B. Weiner
ı					Art Unit	To be determined 1632
L		(Use as many she	ets as		Examiner Name	To be determined: /Wu-Cheng Winston Sher
١	Sheet	3	of	24	Attorney Docket Number	133171.02001

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, diy and/or country where published.	T 2
	BL	Agostini, C., et al. "CD8 T-Cell Infiltration in Extravascular Tissues of Patients with Human Imunodeficiency Virus Infection. Interleukin 15 Upmodulates Co-Stimulatory Pathways Involved in the Antigen Presenting Cells of T-cell Interaction." Blood, (1999) 93: 1277-1286.	
	вм	Anderson, S., et al. "Nef from primary isolates of human immunodeficiency virus type I suppressed surface CD4 expression in human and mouse T cells" <i>J Virol</i> (1993) 67 : 4923-493 1.	
	BN	Anderson D.M. et al., "Chromosomal assignment and genomic structure of II15," Genomics (1995), 25(3):701-6.	
	во	Anether et al., "Interleukin-15 as a potential costimulatary cytokine in CD154 gene therapy of chronic lymphocytic leukemia," <i>Blood</i> (2002) p. 722-723.	
	BP	Arai, et al., "Complete nucleotide sequence of the chromosomal gene for human IL-4 and its expression," J. Immunol. (1989), 142:274-282.	
	BQ	Armitage R.J. et al., "IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation," J. Immunol (1995) Jan 15;154(2):483-90.	
	BR	Ayyavoo, V., et al., "HIV-1 vpr suppresses immune activation and apoptosis through regulation of nuclear factor KB," Nature Medicine, (1997) 3: 1117-1122.	
	BS	Azuma, et al., "Cloning of cDNA for human T-cell replacing factor (interleukin-5) and comparison with the murine homologue," Nucl. Acids Res. (1986), 14:9149-9158.	
	вт	Bamford R.N. et al., "The neuromuscular blocking activity of some monoquatemary androstane derivatives," J Pharm Pharmacol (1971), 23(8):595-9.	
	BU	Borrow, R., et al 1998, "Cytotoxic lymphocyte escape viral variant how important are they in viral evasions of immune clearance in vivo," <i>Immunology Rev</i> , (1998) 164: 37-51.	
	BV	Bourgeois, C., et al. "A Role for CD40 Expression on CD8+ T Cells in the Generation of CD8+ T Cell Memory," 2002, Science 297: 2060-2063.	

Signature	/Wu-Cheng Winston Shen/	Date Considered	07/05/2008
*EVALUED 1-7			

Date

/Wu-Chena Winston Shen/

Examiner

al if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique ortation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandría, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office, U.S. Driven and State of the Papervork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMA control number.

					THE STREET WHEN THE STREET STR
Substi	ute for form 1449B	/PTO			Complete if Known
INE	ODMATIC	M DIG	CLOSURE	Application Number	10/560,650
				Filing Date	05-09-2006
317	STATEMENT BY APPLICANT		First Named Inventor	David B. Weiner	
1				Art Unit	∓e-be-determined 1632
	(Use as many sheets as necessary)		Examiner Name	Forber determined /Wu-Cheng Winston Shen/	
Sheet	4	of	24	Attorney Docket Number	133171.02001

NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Examiner Cite the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue T² Initials 1 No. number(s), publisher, city and/or country where published. Campbell, et al., "Molecular cloning, nucleotide sequence, and expression of the gene encoding RW human eosinophil differentiation factor (interleukin 5)," Proc. Natl. Acad. Sci. USA (1987), 84:6629-Campbell, et al., "Isolation, structure and expression of cDNA and genomic clones for murine RX eosinophil differentiation factor. Comparison with other eosinophilopoietic lymphokines and identity with interleukin-5," Eur. J. Biochem. (1988), 174:345-352. Cao, H., et al. "Cytotoxic T Lymphocyte Cross- Reactivity among Different HIV-1 Type 1 Clades: Implication for Vaccine Development," J Virol; (1997) 71: 86158623. Chang, KH, et al. "Spontaneous Programmed Cell Death of Peripheral Blood Mononuclear Cells **R7** from HIV-Infected Persons is Decreased with IL-15." Yonsei Medical Journal, (2000) 41: 112- 118. Chiu et al., "The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 CA responsive genes," Cell (1988) 54:541-552. Chaudhary, V.K. et al., "A rapid method of cloning functional variable-region antibody genes in CB Escherichia coli as single-chain immunotoxins," Proc. Nat. Acad. Sci. USA (1990) 87:1066-1070. Devos, et al., "Molecular cloning of human interleukin 2 cDNA and its expression in E. coli," Nucl. CC Acids Res. (1983) 11:4307-4323. Finzi, D., et al "Identification of a Reservoir for HIV-1 Patients on Highly Active Antiviral CD Therapy," Science, (1997) 278: 1295-1300. Franklin et al. "Constitutively active MAP kinase kinase (MEK1) stimulates SAP kinase and c-Jun CF transcriptional activity in U937 human leukemic cells," Oncogene. (1995) Dec 7;11(11):2365-74. Furutani, et al.," Complete nucleotide sequence of the gene for human interleukin 1 alpha," Nucl. CF Acids Res. (1985) 14:3167-3179.

Examiner /Wu-Cheng Winston Shen/ Signature	Date Considered	/Wu-Cheng Winston Shen/
---	--------------------	-------------------------

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant is unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

Applicants to inside climation designation institute (replacingly). Applicant is to higher a check mark here it English language Translation is attached.

When USETO to processo an application Confedentiality is governed by 38 U.S. C. 122 and 2000 revells in benefit by the public which is 16 is faund by the USETO to processo an application Confedentiality is governed by 38 U.S. C. 122 and 2000 revells in benefit by the public which is 16 is faund by complete, including gathering, preparing, and submitting the completed application form to the USETO. Time will vary depending upon the indevidual case Any common to the amount of time you require to complete this form and/or suggestions for feedung this burden, should be sent to the Chief in the Chief Confedential C

Approved for use through 07/31/2006, OMB 0661-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

(	Substitute for form 1449B/PT0				Complete if Known		
	INFORMATION	DIS	CLOSUBE	Application Number	10/560,650		
INFORMATION DISCLOSURE				Filing Date	05-09-2006		
STATEMENT BY APPLICANT		First Named Inventor	David B. Weiner				
				Art Unit	To be determined		
	(Use as many she	ets as		Examiner Name	To-bo-determined	/Wu-Cheng W	inston Shen/
✓	Sheet 5	of	24	Attorney Docket Number	133171.02001		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, dy	T 2
	CI	Fuse, et al., Organization and structure of the mouse interleukin-2 gene," Nucl. Acids Res. (1984), 12.9323-9331	
	C1	Gilmore et al., I "The I kappa B proteins: members of a multifunctional family," Trends Genet 1993 Dec;9(12):427-33	
	СК	Girl J.G. et al., "Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15," Embo J (1994), 13(12):2822-30.	
	CL	Giri et al., "Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor," <u>EMBO I</u> , 1995 Aug 1;14(15):3654-63.	
	СМ	Goulder PJ, et al "Late escape from an immunodominant cytotoxic T lymphocyte response associated with progression to AIDS," Nature Medicine, (1997) 3; 212-217.	
	CN	Goulder PJ, et al "Patterns of immunodominance in HIV-1 specific cytotoxic Tlymphocyte response in two human histocompatibility leukocyte antigens HLA identical siblings with HLA A0201 are influence by epitope mutations" [Exp Med. (1997) 185: 1423-1433.	
	со	Grabstein K. et al., "Cloning of a T cell growth factor that interacts with the beta chain of the interleukln-2 receptor," Science (1994) 264:965.	
	CP	Gray et al., "Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity," Nature (1984), 312:721-724	
	CQ	Ho, "Therapy of HIV infections: problems and prospects," Bull. New York Acad. Med. (1996) 73,37-45.	
	CR	Holbrook, et al., "T-cell growth factor: complete nucleotide sequence and organization of the gene in normal and malignant cells," Proc. Natl. Acad. Sci. USA (1984) 81:1634-1638.	
	cs	Howell M.D.et al., "Limited T-cell receptor beta-chain heterogeneity among interleukin 2 receptor- positive synovial T cells suggests a role for superantigen in rheumatoid arthritis," Proc. Nat. Acad. Sci. USA (1991) 88:10921-10925	

Examiner Signature	/Wu-Cheng Winston Shen/	Date Considered	07/05/2008
-----------------------	-------------------------	--------------------	------------

EXAMINEE, Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered include copy of his form with next communication to applicant.

Applicant's unique citation designation number (opinional). Applicant is ophica a check mark here if English language Translation is attached.

This collection of information is required by 37 CPR 1.86. The information is required to obtained were it in prime integrated. In addition, and the LISTFO in process) an application. Confidentiality is governed by 38 U.S.C. 122 and 37 CFR 1.41. This collection is estimated to last 2 yours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual costs Any comments on the activation form you regard to complete this form and/or suggestions for reducing this bring which should be sent to the Chief Complete formation of the Chief Complete for reducing this bring which should be sent to the Chief Complete formation of the Chief Complete for the Chief Complete formation of the Chief Chief Complete formation of the Chief Chief

PTO/SB/08B(07-05)

Approved for use through 07/31/2006 OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

of 24

Sheet

Examiner

	Complete if Known
Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined 1632
Examiner Name	To be determined /Wu-Cheng Winst

07/05/2008

n Shen/ Attorney Docket Number | 133171.02001

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the litem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, dty and/or country where published.	T²
	cu	Kacani, L., et al. "Role of IL-15 in HIV-1 Associated Hypergammaglobulinanemia." Clin Exp linm (1997) 108: 14-18.	***************************************
	cv	Kacani, L., et al. "Interleukin-15 Enhances HIV-1 Driven Polyclonal B-Cell Response in Vitro." Exp and Clin Immun, (1999) 16: 167-179.	
	cw	Kalams, S.A., et al. "The critical need for CD4 help in maintaining effective cytotoxic T Lymphocyte Responses", J. Exp Med. (1998) 188(12): 2199-204	
	сх	Kerkau, T., et al. "The human immunodeficiency virus type I (HIV-I) vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MI+C) class I molecules," J Exp. Med.," (1997) list: 1295-1305.	
	CY	Kim, JJ., et al., "Modulation of amplitutude and direction of in vivo immune responses by co- administration of cassettes with DNA immunogens," Eur. J Immunol. (1998) 28:1089-1103.	
	CZ	Kim JJ., et al. "Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo," Journal of Clinical Investigation. (1999) 103: 869-77.	
	DA	Koup, R., et al "Temporal association of cellular immune responses with the initial control of viremia in primary Human immunodeficiency virus type 1 syndrome" Jof Virol, (1994) 68: 4650- 4655.	
	DB	Koup, RA, "Virus Escape from CTL recognition," J Exp Med, (1994) 180; 779-782.	
	DC	Kozak et al., "An analysis of vertebrate mRNA sequences: intimations of translational control," J Cell Biol (1991), 115(4):887-903	
	DD	Ku, CC., et al. "Control of Homerostasis of CD8 Memory T Cells by Opposing Cytokines," Science, (2000) 288: 675-678.	

Signature	Considered	
*EXAMINER: Initial if reference consider	, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance	nance

/Wu-Cheng Winston Shen/

Date

Exchanges, since a reservoir consolerate, weener of not Officiano is a comprising two interface. Draw the everyor custom is not a commentation to applicate and not considered under copy of the form with next communication to applicate and official control of the communication to applicate and official control of the communication to applicate and official communication to applicate and official control of the communication to applicate the communicati the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief

Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450: DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of infor

Substitute for form 1449B/PTO		Complete if Known
INFORMATION DISCLOSURE	Application Number	10/560,650
	Filing Date	05-09-2006
STATEMENT BY APPLICANT	First Named Inventor	David B. Weiner
	Art Unit	To be determined 1632
(Use as many sheets as necessary)	Examiner Name	To be determined /Wu-Cheng Winston Shen/
Sheet   7   of   24	Attorney Docket Number	133171.02001

		NON PATENT LITERA	TURE DOCUMENTS	3	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, otly and/or country where published.		T²	
	DE	Lee, et al., "Isolation and characterization of stimulatory factor 1 activities and T-cell- and USA (1986) 83:2061-2063.	a mouse interleuk mast-cell-stimula	in cDNA clone that expresses B-cell ting activities," Proc. Natl. Acad. Sci.	
	DF	Lee et al., "Purified transcription factor AP-1 (1987) 49:741-752	interacts with TP.	A-inducible enhancer elements," Cell	
	DG	Lenburg et al. "VPU induced degradation of the cyotplasmic domain of CD4," J Virol, (199	CD4: Requiremen (3) , 7238-7245.	t for specific amino acid residues in	
	DH	Lin, SJ, et al. "Human Immunodeficiency Vir Cytotoxicity Interleukin-2 (IL-2), IL-12, and II	us (HIV) Type-1 C L-15." Clin. Imm. I	GP120-Specific Cell Mediated ninipatli, (1997) 82: 163-173	
	Loubeau, M., et al. 1997, "Jo. Enhancement of Natural Killer and Antibody Dependent Cytotoxic DI Activities of the Periphenal Mononuclear Cells of HIV-Infected Patients by Recombinant IL-15. AIDS" (1997) 16. 137-145				
	Lucey DR., et al. "In Vitro Immunologic and Virologic Effects of Interleukin-15 on Peripheral Blood Mononuclear Cells from Normal Donors and Human Immunodeficiency Virus Type-1 Infected Fatients." Clin Diagna Lab Imm., 4:34-34.				
	DK Maeda, et al., "Cloning of interleukin 2 mRNAs from human tonsils," Biochem. Biophys. Res. Comm. (1983), 115:1040-1047.				
DL Manjunath, N., et al. "Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes," Journal of Clinical Investigation, (2001) 108: 871-878.					
DM  March, et al.," Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs," Nature (1985) 315:641-647		t human interleukin-1			
	Mata, M., et al. "The MHC Class I Restricted Immune Response to HIV-1 gag in Balb/c Mice Selects a Single Epitope That Does not Have a Predictable MHC Binding-Motif and Binds to Kd Through Interactions Between a Clutamine at PS and Pocket D." Jo of Immun., (1998) 16: 2985-2993.		ng-Motif and Binds to Kd Through		
	DO	McCarrick III JW, et al. "Positive-negative sel- chain gene in mouse embryonic stem cells." T	ection gene target	ing with the diphtheria toxin A-	
Examiner Signature					

\*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

"EARINMENT: misal if receivence consistence, mismine or not catastria in an outcombination with merit own, many miss unargued management and not considered. Include copy of this form with mest communication to applicant in a popular management of the management of complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual complete, incoming generating, preparing, and sournainty are completed approximation for the Out I. In this way vegetting your the internation cases. Any comments on the amount of time your requires to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless at contains a valid ONI Scortor number

Substitute for form 1449B/PTO Complete if Known Application Number 10/560,650 INFORMATION DISCLOSURE Filing Date 05-09-2006 STATEMENT BY APPLICANT First Named Inventor David B. Weiner 1632 Art Unit To be determined (Use as many sheets as necessary) /Wu-Cheng Winston Shen/ Examiner Name Sheet of 24 Attomey Docket Number 133171 02001

	,	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	DP	Meyer R., et al.," Cloning of the DNA-binding subunit of human nuclear factor kappa B: the level of its mRNA is strongly regulated by phorbol ester or tumor necrosis factor alpha," Proc. Natl. Acad. 5ci. USA (1991) 88(3) 966-910.	
	DQ	Moore AC., et al. "Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice." Journal of Virology. 76 (1): 243-50,2002 Jan.	
	DR	Murali-Krishna, K., et al. "Persistence of Memory CD8 T Cells in MHC Class I-Deficient Mice," Science, (1999) 286: 1377-1383.	
	DS	Naora H., et al. "Enhanced Survival and Potent Expansion of the Natural Killer Population of HIV Infected Individuals by Exogenous II-15." Immunology Letters, (1999) 68: 359-367.	
	DT	Noma, et al., "Cloning of cDNA encoding the murine lgG1 induction factor by a novel strategy using SP6 promoter," Nature (1986), 319:640-646.	
	DU	Oksenberg, J.R. et al., "Limited heterogeneity of rearranged T-cell receptor V alpha transcripts in brains of multiple sclerosis patients," Nature (1990), 345:344-346.	
	DV	Otsuka, et al., "Structural analysis of the mouse chromosomal gene encoding interleukin 4 which expresses B cell, T cell and mast cell stimulating activities," Nucl. Acids Res. (1987), 15:333-344.	
	DW	Paliard, X et al., "Evidence for the effects of a superantigen in rheumatoid arthritis," Science (1991) 253:325-329.	
	DX	Patki, AH., et al. "Activation of antigen Inducaed Lymphocute Proliferation by Interleukin-15 Without the Mitogenic Effect og Interleukin-2 That May Induce Human Immunodefeciency Virus-1 Expression." (JC, (1996) 95: 616-621.	
	DY	Pennica et al., "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin," Nature (1984), 312:724-729.	
	DZ	Phillips RE, et al. "Human immunodeficiency virus genetic variation'that can escape cytotoxic T cell recognition" Nature, (1991) 354; 453-459.	

Examiner Signature	/Wu-Cheng Winston Shen/	Date Considered	07/05/2008

EXAMINEE, Inflat if reference considered, whether or not citation is in conformance with APEP 609. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant.

Applicant's unique citation designation number (potional), "Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 198. The information is required to botain or retain a benefit by the public which is to life (and by not provided to the public which is to life (and by not public including a public application. Confidentially is governed by 30 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including soft may application. Confidentially is governed by 30 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including soft may applicate the public which is the including soft may be applicated by the public which is the including soft may be applicated by the public which is the including soft may be applicated by the public which is the including soft may be applicated by the public which is the public which is the soft may be applicated by the public which is the public

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

1450.

PTO/SB/08B(07-05)

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number

Substitute for form 1449B/PTO Complete if Known Application Number 10/560,650 INFORMATION DISCLOSURE Filing Date 05-09-2006 STATEMENT BY APPLICANT First Named Inventor David B. Weiner 1632 Art I Init To be determined (Use as many sheets as necessary) Examiner Name /Wu-Cheng Winston Shen/ of 24 Sheet 9 Attorney Docket Number 133171.02001

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, oily and/or country where published.	T 2
	EA	Rauscher et al.," Fos-associated protein p39 is the product of the jun proto-oncogene," Science 1988 240:1010-1016.	
	ЕВ	Rinaldo, C. et al "High Levels of Anti-Human Immunodeficiency Virus Type 1 (HIV-1) Memory Cytotoxic T-Lymphocyte Activity and Low Viral Load Are Associated with Lack of Disease in HIV- 1 Infected Long-Term Nonprogressors," [Viral, (1995) 69: 5838-5842.	
	EC	Rosenberg, ES, et al. "Vigorous HIV-1 Specific CD4 T cell Responses Associated with Control of Viremia," Science, 278: 1447-1450, (1997).	
	ED	Rosenberg, ES, et al "Immune control of HIV-1 after early treatment of acute infection," Nature, (2000) 407: 523	
	EF	Rowland-Jones S., et al "HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant." <i>Lancet</i> , (1993) 341: 860-86.	
	EG	Rowland-Jones S., et al. "HIV-specific T-cells in HIV- exposed but uninfected Gambian women."  Nature Medicine, (1995) 1: 59-64 10.	
	EH	Ruckert et al., "IL-15-IgG2b fusion protein accelerates and enhances a Th2 but not a Th1 immune response in vivo, while IL-2-IgG2b fusion protein inhibits both," Eur Journal Immunol. (1998), Vol.28; 3312-3320.	
	EJ	Serbina NV., et al. "CD4 (+) T cells are required for the development of cytotoxic CD8 (+) T cells during Mycobacterium tuberculosis infection." Journal of Immunology. (2001) 167: 6991-7000.	
	EK	Shankar P., et al., "Impaired function of circulating HIV-specific CD8 (+) T cells in chronic human immunodeficiency virus infection." Blood. (2000) 96 (9): 3094-101 22.	
	EL	Sin JL, et al. "Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo." Human Gene Therapy, 12: 1091-102, 2001.	

Examiner Signature /Wu-Cheng Winston Shen/	Date Considered	07/05/2008	
--	--------------------	------------	--

\*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). 'Applicant is to piace a check mark here if English language Translation is attached.

'Applicant's unique citation designation number (optional). 'Applicant is optional or a check mark here if English language Translation is attached.

This collection of information is required by 37 CPR 109. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Approved for use through 07/31/2005 OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unities a tomains a suid IOMB control number.

Substitute for form 1449B/PTO		Complete if Known
INFORMATION DISCLOSURE	Application Number	10/560,650
	Filing Date	05-09-2006
STATEMENT BY APPLICANT	First Named Inventor	David B. Weiner
	Art Unit	To be determined 1632
(Use as many sheets as necessary)	Examiner Name	To be determined /Wu-Cheng Winston Shen/
Sheet   10   of   24	Attorney Docket Number	133171.02001

	NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, dity and/or country where published.	Т	
	EM	Tagaya, Y., "A Plenotropic Cytokine with Diverse Receptor/Signaling Pathways Whose Expression is Controlled at Multiple Pathways." Immunity (1996) 4: 329-336.		
	EN	Taniguchi, et al., "Structure and expression of a cloned cDNA for human interleukin-2," Nature (1983), 302:305-310.		
	EO	Tanabe, et al., "Molecular cloning and structure of the human interleukin-5 gene," J.Biol. Chem. (1987), 262:16580-16584.		
	EP	Telford, et al., "The murine interleukin 1 beta gene: structure and evolution," Nucl. Acids Res. (1986),14:9955-9963.		
	EQ	Ushio, et al., "Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein," J. Immunol. (1996), 156-4274- 4279.		
	ER	Vieira, et al., "Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFL," <i>Proc. Natl. Acad. Sci. USA</i> (1991), 88:1172-1176.		
	ES	Waldmann et al., "The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens," Annu Rev Immunol (1999),17:19-0.		
	ET	Wierda et al., "CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia," Blood (2000), Vol. 96 pp.2917-2924.		
	EU	Wilkinson P. and Liew F. "Chemoattraction of human blood T lymphocytes by interleukin-15;" J Exp Med (1995), 181(3):1255-9.		
	EV	Williams W.V. et al., "Restricted heterogeneity of T cell receptor transcripts in rheumatoid synovium," J. Clin Invest.(1992) 90:326-333.		
	EW	Wong, J., et al "Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma Viremia," Science, (1997) 278: 1291-1294.		

Examiner Signature /Wu-Cheng Winston Shen/	Date Considered	07/05/2008
--	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 104 per information is required to obtain or estimate other information is required by the USFT to process) an application. Confidentially is given information is required to obtain or estimate to take 2 hours to complete, including agartering preparing, and submitting the completed application from to the USFT. The collection of the complete including agreement preparing, and submitting the completed application from to the USFT. The collection of the complete including the completed application from the USFT. The collection of the complete including and the complete including the complete application from the USFT. The collection of the complete including the complete application from the USFT. The collection of the complete application from the USFT. The collection of the complete including the complete application from the USFT. The collection of the USFT. T

PTO/SB/08B(07-05) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449B/PTO				Complete if Known	,	١
INFORMATION DISCLOSURE				Application Number	10/560,650		1
				Filing Date	05-09-2006		1
SIAI	EMENT B	rΑ	PPLICANT	First Named Inventor	David B. Weiner		1
				Art Unit	To be determined		1
	(Use as many shee	ets as	necessary)	Examiner Name	To be determined	/Wu-Cheng W	nston Shen/
Sheet	11	of	24	Attorney Docket Number	133171.02001		,

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, dky and/or country where published.	T 2
	EX	Wucherpfennig, K.W. et al., "Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein," Science (1990) 248:1016-1019.	
	EY	Yokota, et al., "Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell- and T-cell-stimulating activities," <i>Proc. Natl. Acad. Sci USA</i> (1986), 83:594-5998.	
	EZ	Yokota, et al., "Isolation and characterization of lymphokine cDNA clones encoding mouse and human IgA-enhancing factor and eosinophil colony-stimulating factor activities: relationship to interleukin 5," Proc. Nall. Acad. Sci. USA (1986), 84/3788-3792.	
	FA	Zhang, X., et al., "Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15," J., Immunity, (1998) 8: 591-599.	
	FB	Borrow, P., et al. "Antiviral pressure exerted by HIV-1 specific cytotoxic T lymphocytes during primary infection demonstrated by rapid selection of CTL escape virus" Nature Medicine, (1997) 3: 205-211.	
	FC	Lu et al, "Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions," J. Virol. (1993) Nov;67(11):6542-50.	
The same of the sa	ED	Accession code Swissprot P01585	
	FE	Accession ende Swissprot P01375	
	FF	Accession code D49950	
	FG	Accession code Swissprof 003099	
	FH	Accession code Swissprot P22301	

•				
	Examiner Signature	/Wu-Cheng Winston Shen/	Date Considered	07/05/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CPR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form an/lor suggestions for reducing this busden, should be sent to the Chef information Officer, U.S. Patent and Trademark Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

07/05/2008

Approved for use through 07/31/2006 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless contrains a valid Cort of number

Substitute t	for form 1449B/F	OTO		Complete if Known		
INFO		N DIC	CL COURT	Application Number	10/560,650	
			CLOSURE	Filing Date	05-09-2006	
STAT	EMENT	BY AI	PPLICANT	First Named Inventor	David B. Weiner	
				Art Unit	To be determined	
	(Use as many :	sheets as	necessary)	Examiner Name	To be determined	
Sheet	12	of	24	Attomey Docket Number	133171.02001	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the illem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, dity and/or country where published.	T 2
	FI	Accession code Swissprot P05113	
	FJB	Accession code Swissprot P05112	
	FJb	Accession code Swissprot P01583	
	FK	Genbank Accession Number M21121	
	FL	Genbank Accession Number M81104	
	FM	Genbank Accession Number Y00796	
	FN	Genbank Accession Number J03325	
	FO	Genbank Accession Number Y00093	
	FP	Genbank Accession Number M28526	
	50	Genbank Accession Number J03132	
/	FR	Genbank Accession Number X15606	

Signature Considered Considered Considered Considered Considered ExAMINER: initial if reference considered, whether or not clation is in conformance with MPEP 809, Draw line through classicn if not in conformance.

/Wu-Cheng Winston Shen/

Date

Examiner

and not considered. Include copy of this form with next communication to applicant.

Applicant's funding classing designation number optional, 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 3°C FR 1.98 The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO in process) an explication Confidentiality is governed by 5°U SC. 122 and 3°C FR 1.14 This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the including case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sufficient to the Chief Chief

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute	for form 1449B/P	то		Complete if Known		
INITO	DIATIO	u Dic	CLOSURE	Application Number	10/560,650	
				Filing Date	05-09-2006	
STAT	EMENT	BY AI	PPLICANT	First Named Inventor	David B. Weiner	
				Art Unit	To be determined	
	(Use as many s	heets as	necessary)	Examiner Name	To be determined	
Sheet	13	of	24	Attorney Docket Number	133171.02001	

		NON PATENT LITERA	TURE DOCUMENTS		
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL Li the item (book, magazine, journal, serial, s number(s), publisher, c	ymposium, catalog, etc	.), date, page(s), volume-issue	T²
/	FS	Genbank Accession Number X69819			
	FR	Genbank Accession Number Y00636			
	FU	Germank Accession Number M37435			
	FV	Genbank Accession Number M27087	/		
	FW	Genbank Accession Number M10663			
	FX	Genbank Accession Number M11220	<		
	FY	Genbank Accession Number X03665			
	FZ	Genbank Accession Number X03656			
	GA	Genbank Accession Number M37435			
	Co	Genbank Accession Number M13982			
	GC	Genbank Accession Number M23442			\
Examiner Signature		/Wu-Cheng Winston Shen/	Date Considered	07/05/2008	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

Executives: Initial infection consistence with residence for contention in conformation with the Per-900. Lines with the trough critical in in conformation in the property of the property of

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. Office, V.S. Policy Affice of the Packet Mark Office of t

1	Substitute	for form 1449B/PT	го		Complete if Known		
	INIFO	D14 A T10 A		OL OCUPE	Application Number	10/560,650	
				CLOSURE	Filing Date	05-09-2006	
	STAT	EMENT	BY AI	PPLICANT	First Named Inventor	David B. Weiner	
					Art Unit	To be determined	
		(Use as many si	heets as	necessary)	Examiner Name	To be determined	
↸	Sheet	14	of	24	Attorney Docket Number	133171.02001	

Examiner No.1  Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), voluminals *  Genbank Accession Number 137414.  Genbank Accession Number M67454.  Genbank Accession Number M67454.  Genbank Accession Number M60275.  Genbank Accession Number M60275.  Genbank Accession Number M60275.  Genbank Accession Number M52977.  Genbank Accession Number M52977.  Genbank Accession Number M52977.	
Genbank Accession Number M67454.  GF Cenbank Accession Number M63121.  GG Cenbank Accession Number M60275.  GH Genbank Accession Number M32977.  GI Genbank Accession Number J01156.  Genbank Accession Number J01156.	
GF Cenbank Accession Number M63121.  GG Cenbank Accession Number M60275.  GH Genbank Accession Number M32977.  GI Genbank Accession Number M32977.  GI Genbank Accession Number J04156.	
GF GG Cenbank Accession Number M60275. GH Cenbank Accession Number M32977. Gi Genbank Accession Number J04156. Genbank Accession Number J04156.	
GG Genbank Accession Number M32977. GI Genbank Accession Number J04156. Genbank Accession Number J04156.	
GH Gi Genbank Accession Number J04156. Genbank Accession Number M57246	
Gil Genbank Accession Number M57249	
Genbank Accession Number M57259.	
\ \ \ \ \	
GK Genbank Accession Number U43628.	
GL Genbant Accession Number U80016.	
Genbank Accession Number AF180563 (P40 mRNA)	
Gn Genbank Accession Number AF180562 (P35 mRNA)	

Examiner Signature	/Wu-Cheng Winston Shen/	Date Considered	07/05/2008

"EXAMINER: Initial if reference considered, whether or not claisin is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional)." Applicant is to place a check mark here if English language Translation is attached.

Applicates funding damaged in designation interfered because the properties of pages of the properties of the properties

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Papervork Reduction Act of 1995, no persons are required to respond to a collection of information unless it orbitisms and of OMB control number.

Substitute fe	or form 1449B/PTC	)		Complete if Known		
INITOT	MATION	DIE	CLOSURE	Application Number	10/560,650	
				Filing Date	05-09-2006	
STATI	EMENT B	ΥA	PPLICANT	First Named Inventor	David B. Weiner	
				Art Unit	To be determined	
	(Use as many she	ets as	necessary)	Examiner Name	To be determined	
Sheet	15	of	24	Attorney Docket Number	133171.02001	

		NON PATENT LITERA	TURE DOCUMENTS		
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LE the item (book, magazine, journal, serial, s number(s), publisher, ci	ymposium, catalog, etc.	), date, page(s), volume-issue	T ²
	GO	GENBANK Accession number A37867			
	G	GENBANK Accession number \$17233			
	GQ	GENBANK Accession number A42024			
	GR	GENBANK Accession number A57034			
	GS	GENBANK Accession nutrition U34819			
	GT	GENBANK Accession number U34820			
	GU	GENBANK Accession number U24821			
	GV	GENBANK Accession number U34822			
	GW	GENBANU Accession number U35002			
	SH	GENBANK Accession number U35003			
/	GY	GENBANK Accession number U35004			
Examiner Signature		/Wu-Cheng Winston Shen/	Date Considered	07/05/2008	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant is ruingle citation designation number (opinional, "Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO is processed) an application. Confidentiating is governed by 38 US C 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including githering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual complete in the complete is the second for reducing the variety of the complete file from another suggestions for reducing the buriety included to earlier to the Chair Confidence of the C

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449B/P	то		Complete if Known		
INFORMATION DISCLOSURE				Application Number	10/560,650	
				Filing Date	05-09-2006	
SIAI	EMENII	BYA	PPLICANT	First Named Inventor	David B. Weiner	
				Art Unit	To be determined	
	(Use as many s	sheets as	necessary)	Examiner Name	To be determined	
Sheet	16	of	24	Attorney Docket Number	133171.02001	

		NON PATENT LITERA	TURE DOCUMENTS		
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LE the item (book, magazine, journal, serial, s number(s), publisher, c	ymposium, catalog, e	tc.), date, page(s), volume-issue	T 2
	GZ	GENBANK Accession number U35005			
	FIA	GENBANK Accession number L31951			
	нв	GENBANK Accession number M85164			
	нс	GENBANK Accession number M85165			
	HD	GENBANK Accession number Y10256			
	HE	GENBANK Accession number U78798			
	HF	GENBANK Accession number NM001569			
	HG	GENBANK Accession number U70451			
	нн	GENBANK Accession number L19067			
		GENBANK Accession number U66243			
/	HJ	GENBANK Accession number M36711			
Examiner Signature		/Wu-Cheng Winston Shen/	Date Considered	07/05/2008	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

and not considered. Include copy of this form with next communication to applicant

Applicant's unique citation designation number (opionals). Applicant is to place a check mark here it English language Translation is attached

This collection of information is required by 37 CRR 1 98. The information is required to obtain or retain a benefit by the public which is to file (and by

the USPTO to process) an application. Confidentiality is governed by 35 US C. 122 and 37 CRR 1-14. This collection is estimated to take? Jours to

complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual College, including judgeting, proporting, and accompanies opportunition in the USF LO. This will vary opportunity opportunition of the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Akexandria, VA 22313-1450 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO	Complete if Known		
INFORMATION DIGGLOCUDE	Application Number	10/560,650	
INFORMATION DISCLOSURE	Filing Date	05-09-2006	
STATEMENT BY APPLICANT	First Named Inventor	David B. Weiner	
	Art Unit	To be determined	
(Use as many sheets as necessary)	Examiner Name	To be determined	
Sheet 17 of 24	Attorney Docket Number	133171.02001	

		NON PATENT LITERA	ATURE DOCUMENTS		
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL L the item (book, magazine, journal, serial, number(s), publisher,	ETTERS), title of the art symposium, catalog, etc. city and/or country where	), date, page(s), volume-issue	T 2
	нк	GENBANK Accession number J04111			
	Pho	GENBANK Accession number K00650			
	нм	GBNBANK Accession number L09753	., .,		
	HN	GENBANK Assession number M83554			
	но	GENBANK Accession number M29039			
	HP	GENBANK Accession number L14542			
	HQ	GENBANK Accession number Ve 1512			
	HR	GENBANK Accession number X54868			
	нѕ	GENBANK Accession number X54867			
	-	GENBANK Accession number U65416			
/	ни	GENBANK Accession number X92841			
Examiner		/Wu-Cheng Winston Shen/	Date	07/05/2008	

Signature Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional), 2 Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449B/PTO Complete if Known Application Number 10/560,650 INFORMATION DISCLOSURE Filing Date 05-09-2006 STATEMENT BY APPLICANT First Named Inventor David B. Weiner Art Unit To be determined (Use as many sheets as necessary) Examiner Name To be determined of 24 Sheet 18 Attorney Docket Number 133171.02001

		NON PATENT LITERAT	TURE DOCUMENTS		
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LE the item (book, magazine, journal, serial, sy number(s), publisher, ci	mposium, catalog,	etc.), date, page(s), volume-issue	T 2
	HV	GENBANK Accession number TRAIL-R2 AF	016849.		
	FML.	GENBANK Accession number TRAIL-R3 AF	014794.		
	нх	GENBANK Accession number TRAIL-R4 AF	021232.		
	нү	GENBANK Accession number U37518.			
	HZ	GENBANK Accession number AF023849.			
	IA	GENBANK Accession number L22473.			
	IB	GENBANK Accession number 107414.			
	IC	GENBANK Accession number Y09908.			
	ID	GENBANA Accession number X91233.			
		GENBANK Accession number X94223.			
/	IF	GENBANK Accession number X94222.			
T					
Examiner Signature		/Wu-Cheng Winston Shen/	Date Considered	07/05/2008	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's runging calation designation number (options)<sup>2</sup>, Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confriendistily as gowered by 38 U.S. C. 122 and 37 CFR 1.14. This collection is estimated to base 2 hours to complete, including gathering, preparing, and submitting the completed application from to the USPTO. There will vary depending upon the individual complete, including gathering, preparing, and submitting the completed application from to the USPTO. There will vary depending upon the individual including gathering, preparing, and submitting the complete his form and/or suggestions for reacturing this baset, should be seried to the Client Individual Complete in the Client Individual Complete Individual

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Pacework Reduction Act of 1995, no persons are maintain to respond to a collection of information pulses it motions a valid CMB control under

Sul	bstitute for fo	rm 1449B/PTO			Complete if Known		
- 16	INFORMATION DISCLOSURE				Application Number	10/560,650	
					Filing Date	05-09-2006	
S	TATEN	MENT BY	ΥA	PPLICANT	First Named Inventor	David B. Weiner	
					Art Unit	To be determined	
	(Use	as many shee	ets as	necessary)	Examiner Name	To be determined	
Sh	neet 19	)	of	24	Attorney Docket Number	133171.02001	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, dity and/or country where published.	T <sup>2</sup>
	IG	GENBANK Accession number AF031167	
	M	GENBANK Accession number U37518	
	11	SenBank Accession No. AF068868 (Sep. 5, 1998).	
	IJ	Genbank Absession Number U13699.	
	IK	Genbank Accession Nomber U13697.	
	IL	Genbank Accession Number U0333	
	IM	Genbank Accession number U13698	
	IN	Genbank Accession Number AF018657.	
	Ю	Genbank Accession Number AF020501	
	IP	Genback Accession Number AF022386	
	10	Genbank Accession Number AF012535	
	IR	Genbank Accession Number U90875	/

Examiner Signature	/Wu-Cheng Winston Shen/	Date Considered	07/05/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant.

\*Applicant\*\* unique citation designation number (opinions) \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 3T CPR 198. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 59 US CP 122 and 3T CPR 1.14 This collection is estimated to take 2 hours to complete, including pathographic, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any common on the amount of time you require to complete this form and/or suggestions to tracking this brains, should be suit to the Chief of the

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPATMENT OF COMMENCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless to retains a valid CMB control number

	Substitute	for form 1449B	/PTO			Complete if Known		
	INFORMATION DISCLOSURE				CLOCUDE	Application Number	10/560,650	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use as many sheets as necessary)					Filing Date	05-09-2006	
						First Named Inventor	David B. Weiner	
						Art Unit	To be determined	
_						Examiner Name	To be determined	
	Sheet	20		of	24	Attorney Docket Number	133171.02001	

	T	NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
\\	IS	Genbank Accession Number M14764	
	1	Genbank Accession Number U94512	
	IU	Genback Accession Number U78029	
	IV	Genbank Accession Number U74611	
	ıw	Genbank Accession Number 076381	
	IX	Genbank Accession Number Y09392	
v week .	IY	Genbank Accession Number M58286	
	ΙZ	Genbank Accession Number M67454	
	JA	Genbank Accession Number M67454	
	JB	Genbank Accession Number X63717	

-			
Examiner Signature	/Wu-Cheng Winston Shen/	Date Considered	07/05/2008

\*EXAMINER. Initial if raference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.

Applicants unique classification designation funding of policinal in the plant and the plant and the plant and in the plant which is to life (and by the USPT) to process jar application. Confidentially is governed plant and in the plant and in

U.S. Palent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a calcidation of information weak Contrast or weak CMB control number
for form 1448BPTO

Complete if Known

	Substitute for form 1449B/PTO		Complete if Known		
	INFORMATION DIS	CLOSUBE	Application Number	10/560,650	
			Filing Date	05-09-2006	
	STATEMENT BY A	PPLICANT	First Named Inventor	David B. Weiner	
			Art Unit	To be determined	
	(Use as many sheets as	necessary)	Examiner Name	To be determined	
(	Sheet 21 of	24	Attorney Docket Number	133171.02001	

		NON PATENT LITERA	TURE DOCUMENTS		
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LE the item (book, magazine, journal, serial, sy number(s), publisher, ci	mposium, catalog	, etc.), date, page(s), volume-issue	T²
	JC	Genbank Accession Number X51602			
	38	Genbank Accession Number X94263			
	JE	Gerbank Accession Number M25322			
	JF	Genbank Accession Number X16150			
	JG	Genbank Accession Number 569738			
		>			
	JH	Genbank Accession Number M29130			
	JI	Genbank Accession Number M14362			
	'n	Genbani Accession Number M24736			
		Genbank Accession Number U72395			
/	JL	GENBANK Accession number AH006173			
Examiner Signature		/Wu-Cheng Winston Shen/	Date Considered	07/05/2008	

\*EXAMMER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.

Applicant's unique citation designation number (optional). "Applicant is to place a check mark here if English language Transistation is to stanched.

This collection of Information is required by 37 CFR 1.88 in information is required to obtain or retain a benefit by in public which is 61 file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14 This collection is estimated to take 2 hours to complete, including gathering, prepriate, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Child information Office. U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 2231-1450, D NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B(07-05)

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute fo	or form 1449B/PTO	1		Complete if Known		
INICOE	MATION	DIC	CLOSURE	Application Number	10/560,650	
				Filing Date	05-09-2006	
SIAII	EMENT B	YA	PPLICANT	First Named Inventor	David B. Weiner	
				Art Unit	To be determined	
	(Use as many she	ets as	necessary)	Examiner Name	To be determined	
Sheet	22	of	24	Attorney Docket Number	133171.02001	

Under the Panerwork Reduction Act of 1995, no norsons are requi

		NON PATENT LITERA	TURE DOCUMENTS		
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LE the item (book, magazine, journal, serial, s number(s), publisher, c	ymposium, catalog	, etc.), date, page(s), volume-issue	T 2
	JO	GENBANK Accession number X54869			
	38	GENBANK Accession number AJ001684			
	JQ	GENBANK Accession number U96846	-		
	JR	GENBANK Accession number BC021101		/	
	JS	GENBANK Accession number BC005250			
	JT	GENBANK Accession number BC002878			
	JU	GENBANK Accession number Me1126			
	JV	GENBANK Accession number J02893			
	JW	GENBANK Accession number X15102			
		Accession code Swissprot P01374			
/	JY	GENBANK Accession number U96845			
Examiner Signature		/Wu-Cheng Winston Shen/	Date Considered	07/05/2008	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicants unique citation designation number (optional). Applicants to judge a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO in process) an application. Confiderability is governed by 39 US. C. 122 and 37 CFR 1.14. This collection is estimated to stake 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO Time will vary depending upon the individual process. Any comments on the amount of time you require to complete this form and/or suggestions for tracking the burstle should be set in the Cheff of the Che

Approved for use through 07/31/2006 OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTIMENT OF COMMERCE
Under the Pacework Reduction Act of 1995, no persons are required to rescond to a callection of information unless it contains a valid CMB control number

Substitute	for form 1449B/PT0	)	Complete if Known		
11150	D T.O.	DIGG! COURT	Application Number	10/560,650	
		DISCLOSURE	Filing Date	05-09-2006	
STAT	EMENT B	Y APPLICANT	First Named Inventor	David B. Weiner	
			Art Unit	To be determined	
	(Use as many she	ets as necessary)	Examiner Name	To be determined	
Sheet	23	of 24	Attorney Docket Number	133171.02001	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	JZ	GENBANK Accession number AB007839	
	M	GENBANK Accession number X54870	
	КВ	OCNBANK Accession number AF461811	
	кс	GENBANK Accession number X79929	
	KD	GENBANK Accession number X75962	
	KE	GENBANK Accession number AF3332.3	
	KF	GENBANK Accession number 14/019047	
	KG	GENBANK Accession number AF018253	
	кн	GENBANK Accession number AF016266	
		GENBANK Accession number U90875.	
$\overline{}$	KJ	GENBANK Accession Number U72763	

Examiner Signature	/Wu-Cheng Winston Shen/	Date Considered	07/05/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant.

\*Applicant\* unique citation designation number (opinosa). \*Applicant is unique citation designation number (opinosa). \*Applicant is unique citation designation number (opinosa). \*Applicant is unique citation designation number (opinosa). \*Applicant sunique citation designation number (opinosa). \*Applican

Applicables unique distant neisgration number (capions), a page-capion and page of mark here it engine integrates in integrates in a page of a capion of the capion of the

PTO/SB/08B(07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number Substitute for form 1449B/PTO Complete if Known Application Number 10/560,650 INFORMATION DISCLOSURE 05-09-2006 Filing Date STATEMENT BY APPLICANT First Named Inventor David B. Weiner 1632 Art Unit To be determined (Use as many sheets as necessary) To be determined. Wu-Cheng Winston Shen/ Examiner Name of 24 Sheet 24 Attorney Docket Number 133171.02001

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where publisher.	T²
	км	Onu, A., et al. "Regulation of IL-15 secretion via the leader peptide of two IL-15 isoforms.", Journal of Immunology, (1997) 158: 255-262.	
	KN	Suzuki, K. et al., "NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: imunogene therapy using a highly secretable form of interleukin-15 gene transfer.", Journal of Leukocyte Biology, (2001) 69-531-537.	
	KR	Yang, J-S et al., "Induction of potent Th1-type immune responses from a novel dna vaccine for west nile virus, "Journal of Infectious Diseases"; (2001) 184:809-816	
	KS	Rueckert, R. et al., "IL-15-IgC2b fusion protein accelerates and enhances a Th2 but not a Th1 immune response in vivo, while IL-2-IgC2b fusion protein inhibits both.", European Journal of Immunology (1998) 28: 3312-3330	
	_		
	-		
			-
			1

Examiner Signature	/Wu-Cheng Winston Shen/	Date Considered	07/05/2008

\*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant.

\*Availating from the citation desiration number (political). \*Applicant is to place a check mark here if English language Translation is attached.

Applicants unique clation designation number (optional). Applicant is to place a check mark here if English language Translation is satached.

This collection of information is required by 37 CFR 19.8 The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14 This collection is estimated to take 2 hours to complete, including pathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chile information Officer. U. S. Patent and Trademank Officer, U.S. Department of Commerce, P.O. Box 4450, Absandria, VA 22314-3450. ONTO SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.